InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the complete record of transactions filed by Thomas Stephen Basil. Officer active across 2 companies, notably Eliem Therapeutics, Inc.. In total, 7 disclosures have been published. Split: 0 buy · 2 sells. Total volume traded: €597k. Activity tracked since 7 August 2025. The latest transaction was filed on 25 February 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations
Thomas Stephen Basil is a director of Climb Bio, Inc. and Eliem Therapeutics, Inc. The declarant has 7 filings in total, and in the recent filings available, the transactions cover the period from 2024-06-27 to 2026-02-27, with EUR 0 in buys and EUR 596976 in sells, and the most frequent transaction nature is Levée d'options.